Smd / Antioxydogramme: Diagnostic and predictive kit For myelodysplasia and chronic myeloid leukaemia

MARKET

• The diagnostics market covers several very different disciplines or technological approaches.

• The global market for In Vitro Diagnostics (IVD) was estimated in 2011 at approximately

USD44B and included instrument and consumable sales. The market is segmented according

to analysis types and/or targeted pathologies.

• The main market is the U.S. with nearly 47% of market share.

TECHNOLOGY DESCRIPTION

• The technology developed is a kit that helps decisionmaking for the desired level that

follows genes expression involved in oxidation reduction. A profile is obtained, called «

Antioxydogram », for each patient and it classifies the variants observed amongst myelodysplasia

syndromes.

• The kit can also do longitudinal tracking of patients in treatment and helps the clinicians’

decisionmaking in order to understand how a patient will react to the prescribed treatment.

Competitive ADVANTAGES

• Classification of myelodysplasias

• Longitudinal tracking of patients in treatment.

• Decisionmaking aid for the choice of therapy

• Easy to implement in a hospital environment.